Cargando…
Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema
BACKGROUND: Diabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has demonstrated that may improve both central macular thickness (CMT) and best corrected visual acuity (BCVA). This study aimed to evaluate the effect...
Autores principales: | Castro-Navarro, Verónica, Cervera-Taulet, Enrique, Navarro-Palop, Catalina, Monferrer-Adsuara, Clara, Hernández-Bel, Laura, Montero-Hernández, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330395/ https://www.ncbi.nlm.nih.gov/pubmed/30634940 http://dx.doi.org/10.1186/s12886-018-1022-9 |
Ejemplares similares
-
Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant
por: Castro-Navarro, Verónica, et al.
Publicado: (2022) -
Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa
por: Örnek, Nurgül, et al.
Publicado: (2016) -
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
por: Pacella, Elena, et al.
Publicado: (2013) -
Dexamethasone Intravitreal Implant (Ozurdex) for Long-Term Macular Edema after Epiretinal Membrane Peeling Surgery
por: Chang, Yo-Chen, et al.
Publicado: (2018) -
Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema
por: Furino, Claudio, et al.
Publicado: (2017)